KINDOSYS

Serial Number 97798263
731

Registration Progress

Application Filed
Feb 16, 2023
Under Examination
Feb 20, 2024
Approved for Publication
Dec 26, 2023
Published for Opposition
Dec 26, 2023
Registered

Attorney Assistance

Statement of Use Due - Extension 2 Granted
Due: Aug 20, 2025 39 days

Trademark Image

KINDOSYS

Basic Information

Serial Number
97798263
Filing Date
February 16, 2023
Published for Opposition
December 26, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
731
Status Date
Jan 28, 2025
Application
Pending
Classes
005

Rights Holder

Saol International Development Ltd.

99
Address
H.P. House
21 Laffan Street
Hamilton HM09
BM

Ownership History

Saol International Development Ltd.

Original Applicant
99
Hamilton BM

Saol International Development Ltd.

Owner at Publication
99
Hamilton BM

Legal Representation

Attorney
Jeffrey H. Handelsman

USPTO Deadlines

Next Deadline
39 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
August 20, 2025
Extension Available
Until February 20, 2025

Application History

16 events
Date Code Type Description
Jan 29, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 29, 2025 EX2G S SOU EXTENSION 2 GRANTED
Jan 28, 2025 EXT2 S SOU EXTENSION 2 FILED
Jan 28, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 25, 2024 EX1G S SOU EXTENSION 1 GRANTED
Jul 25, 2024 EXT1 S SOU EXTENSION 1 FILED
Jul 25, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 25, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 20, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 26, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 26, 2023 PUBO A PUBLISHED FOR OPPOSITION
Dec 6, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 17, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 15, 2023 DOCK D ASSIGNED TO EXAMINER
Mar 7, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 20, 2023 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of mitochondrial diseases, metabolic diseases, cardiopulmonary diseases, and cancers

Classification

International Classes
005